The Patent Finder
CB

CSL Behring GmbH

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

40 patents currently held

4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Aug 2028. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
7
Ending by 2030
Aug 2028
Next term end
32
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Compositions Comprising Secretory-Like Immunoglobulins US 10,221,233
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2034.
Ends Oct 2034 · High confidence
Also notable
Hydrophobic Charge Induction Chromatographic Protein Depleted Solution US 11,426,680
A family of 7 related applications built on the 2022 grant. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Ends Mar 2033 · High confidence
Also notable
Methods for Purification of ALPHA-1-Antitrypsin and Apolipoprotein A-1 US 8,962,802
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2028.
Ends Aug 2028 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 4 to 18, 2027 · next Feb 4
  • 1 fee due Mar 5, 2027
    The maintenance fee for A Blood Coagulation Factor Replacement Product for Use in the Treatment or Prophylaxis of Bleedings (US 11,744,880) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
  • 1 fee due Apr 15, 2027
    The maintenance fee for Therapeutic Agent for Amniotic Fluid Embolism (US 10,441,631) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
  • 1 fee due May 12, 2027
    The maintenance fee for Combination Therapy Using Immunoglobulin and C1-Inhibitor (US 10,471,142) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,962,802Methods for Purification of ALPHA-1-Antitrypsin and Apolipoprotein A-1
In force
 · Medium confidence
In forceMedium confidence
US 8,394,768Synergistic Therapeutic Use of Prothrombin Complex Concentrates with Fviii Concentrates
In force
 · High confidence
In forceHigh confidence
US 9,095,564Von Willebrand Factor or Factor VIII and Von Willebrand Factor for the Treatment of Coagulopathy Induced by Inhibitors of Thrombocytes
In force
 · High confidence
In forceHigh confidence
US 10,137,165Factor H for the Treatment of Chronic Nephropathies and Production Thereof
In force
 · High confidence
In forceHigh confidence
US 8,632,773Antibody Composition with Altered Fab Sialylation
In force
 · High confidence
In forceHigh confidence
US 8,603,979Von Willebrand Factor or Factor VIII and Von Willebrand Factor for the Treatment of Coagulopathy Induced by Inhibitors of Thrombocytes
In force
 · High confidence
In forceHigh confidence
US 7,939,632Proteolytically Cleavable Fusion Proteins with High Molar Specific Activity
In force
 · High confidence
In forceHigh confidence
US 9,107,902Use of VWF Stabilized Fviii Preparations and of VWF Preparations Without Fviii for Extravascular Administration in the Therapy and Prophylactic Treatment of Bleeding Disorders
In force
 · High confidence
In forceHigh confidence
US 9,352,016Factor XII Inhibitors for the Administration with Medical Procedures Comprising Contact with Artificial Surfaces
In force
 · High confidence
In forceHigh confidence
US 9,624,307Factor XII Inhibitors for the Treatment of Silent Brain Ischemia and Ischemia of Other Organs
In force
 · High confidence
In forceHigh confidence
10 of 40 patents shown.
Pro members see all 40.
Pro members: see all 40 patents
Also on record, not counted in the 40: 4 patents in force now held by others · 49 patents ended · 26 applications pending · 51 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited